News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Isabelle Ray-Coquard: New publication from ENGOTov25 Paola-1 study
centreleonberard.fr
Dec 12, 2024, 16:06

Isabelle Ray-Coquard: New publication from ENGOTov25 Paola-1 study

Isabelle Ray-Coquard, Medical Oncologist at Léon Bérard Center, shared a post on LinkedIn, about a paper by her and colleagues, published in Annals of Oncology:

“Paola-1 publications, new episode in Annals of Oncology 2024 revealing that subsequent therapies can be impacted differently after 1st line maintenance with parpi and bevacizumab or bevacizumab alone…

Very proud to share this academic international collaborative new publication from ENGOTov25 Paola-1 study.”

“Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.”

Authors: P. Harter, C. Marth, M. Mouret-Reynier, E. Pujade-Lauraine, I. Ray-Coquard et al.

Isabelle Ray-Coquard: New publication from ENGOTov25 Paola-1 study

More posts featuring Isabelle Ray-Coquard.

Annals of Oncology cancer ENGOTov25 Paola-1 Isabelle Ray-Coquard OncoDaily Oncology
Special Coverage
Voices
Sep 8, 2025, 09:53
David Planchard Highlights FLAURA2 OS Benefit Discussion at WCLC 2025
Science
Sep 8, 2025, 09:46
Amol Akhade: WCLC25 Highlight - HARMONi-A Trial in EGFR-mutant NSCLC
Science
Sep 8, 2025, 09:35
Drew Moghanaki: Shift in Radiation Therapy Intent for NSCLC Over the Past Decade
Science
Sep 8, 2025, 09:23
Bassam Sonbol: Randomized Phase II Trial of Pazopanib vs Placebo in Extrapancreatic NETs
Science
Sep 8, 2025, 09:06
Pat Soon-Shiong: Allowing Immune System to Cure the Cancer
Insight
Sep 8, 2025, 08:57
Andreas Charalambous: New Lancet Commission for Lung Cancer
Voices
Sep 8, 2025, 08:51
Roberto Ferrara: Tailoring Combination Treatments to ICI Resistance and Biomarkers
Voices
Sep 8, 2025, 08:44
Katy Beckermann: Strong Correlation Between Uptake and Tissue FAP Expression
Science
Sep 8, 2025, 08:34
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
Voices
Sep 8, 2025, 08:22
Vun-Sin Lim Highlights New IASLC Journals Lounge at WCLC25
Voices
Sep 8, 2025, 08:21
Ravindran Kanesvaran: The Best of Collaborative GU Oncology Education
Voices
Sep 8, 2025, 08:19
Harpreet Singh Showcases Biotech on the Main Stage at WCLC2025